Design Therapeutics, Inc. (DSGN)
$
3.73
-0.28 (-7.51%)
Key metrics
Financial statements
Free cash flow per share
-0.8399
Market cap
211.7 Million
Price to sales ratio
0
Debt to equity
0.0094
Current ratio
28.3686
Income quality
0.8444
Average inventory
0
ROE
-0.2285
Technology
Technology – consumer electronics
Largecap
With a market cap of 121,78 bil stock is ranked 1
Low risk
ISS score of this stock is ranked 1
Company description
Profile
Design Therapeutics, Inc. is a preclinical-stage biopharmaceutical company focused on developing therapies for genetic diseases linked to nucleotide repeat expansions. Its portfolio includes treatments for Friedreich Ataxia, a monogenic, autosomal recessive disorder that progressively impairs multiple organ systems reliant on mitochondrial function, ultimately causing neurological, cardiac, and metabolic complications. The company is also working on therapies for Myotonic Dystrophy Type-1 (DM1), a dominantly-inherited progressive neuromuscular disease affecting the skeletal muscle, heart, brain, and other systems. Additionally, Design Therapeutics is advancing its GeneTAC product candidate portfolio to target a variety of other nucleotide repeat expansion-driven genetic conditions, including Fragile X syndrome, spinocerebellar ataxias, amyotrophic lateral sclerosis, frontotemporal dementia, Huntington disease, and spinobulbar muscular atrophy. In its recent financial report, the company revealed a net loss of -$49,588,000.00 indicating challenges in its operations. Despite these difficulties, the gross profit stands at $0.00 highlighting the company's performance from core activities. The diluted earnings per share (EPS) is -$0.88 taking into account possible share dilution, while the revenue achieved was $0.00 signifying its focused efforts in a niche market. The company’s stock is identified by the symbol '$DSGN' in the financial market. On the market front, Design Therapeutics’ stock is priced affordably at $4.01 making it an attractive option for budget-conscious investors. The stock also exhibits a low average trading volume of 136,071.00 reflecting reduced activity in the market. With a market capitalization of $211,747,251.00 the company is categorized as a small-cap player, positioning it well within the industry. Being a key contributor to the Biotechnology industry, Design Therapeutics significantly influences the overall market landscape. Furthermore, it operates within the Healthcare sector, continuously driving innovation and growth amidst the evolving dynamics of the biopharmaceutical domain.
Is Design Therapeutics, Inc. (DSGN) a good investment?
Investing in Design Therapeutics, Inc. (DSGN) depends on multiple factors, including revenue growth, profit margins, debt-to-equity ratio, earnings per share, and return on equity. Analysts have rated it as B-, with a Bullish outlook. Always conduct your own research before investing.
What is Design Therapeutics, Inc. (DSGN)'s stock forecast?
Analysts predict Design Therapeutics, Inc. stock to fluctuate between $2.60 (low) and $7.77 (high) in the next 365 days, reflecting market expectations and potential volatility.
What is Design Therapeutics, Inc.'s market capitalization?
As of 2025-05-30, Design Therapeutics, Inc.'s market cap is $211,747,251, based on 56,768,700 outstanding shares.
How does Design Therapeutics, Inc. compare to competitors like Meta Platforms, Inc. Class A Common Stock?
Compared to Meta Platforms, Inc. Class A Common Stock, Design Therapeutics, Inc. has a Lower Market-Cap, indicating a difference in performance.
How can I buy Design Therapeutics, Inc. (DSGN) stock?
To buy Design Therapeutics, Inc. (DSGN) stock: Open a brokerage account (e.g., Robinhood, TD Ameritrade, E-Trade). Search for DSGN. Place an order (Market, Limit, etc.).
What is the best time to invest in Design Therapeutics, Inc.?
The best time to invest depends on market trends and technical indicators, which show a Bullish trend based on economic conditions and company performance.
How did Design Therapeutics, Inc. perform in the last earnings report?
Revenue: $0 | EPS: -$0.88 | Growth: -26.05%.
Where can I find Design Therapeutics, Inc.'s investor relations reports?
Visit https://www.designtx.com/investor-relations for detailed financial reports.
Where can I find historical stock prices for Design Therapeutics, Inc.?
You can explore historical data from here
What is the all-time high and low for Design Therapeutics, Inc. stock?
All-time high: $50.50 (2021-03-26) | All-time low: $1.94 (2023-08-22).
What are the key trends affecting Design Therapeutics, Inc. stock?
Key trends include market demand, economic conditions, interest rates, and industry competition, which influence the stock's performance.
News
globenewswire.com
4 days ago
CARLSBAD, Calif., May 28, 2025 (GLOBE NEWSWIRE) -- Design Therapeutics, Inc. (Nasdaq: DSGN), a clinical-stage biotechnology company developing treatments for serious degenerative genetic diseases, today announced that management will present during the 2025 Jefferies Global Healthcare Conference on Wednesday, June 4, 2025, at 2:35 p.m.
globenewswire.com
19 days ago
CARLSBAD, Calif., May 13, 2025 (GLOBE NEWSWIRE) -- Design Therapeutics, Inc. (Nasdaq: DSGN), a clinical-stage biotechnology company developing treatments for serious degenerative genetic diseases, today announced that management will participate in a fireside chat during the 2025 RBC Capital Markets Healthcare Conference on Tuesday, May 20, 2025, at 8:00 a.m. ET in New York.
globenewswire.com
24 days ago
Phase 1 Single Ascending Dose Trial of DT-216P2 for Friedreich Ataxia (FA) Program Ongoing Reported Favorable Phase 1 Data for DT-168 for Fuchs Endothelial Corneal Dystrophy (FECD) Program Well-Capitalized with Cash and Securities of $229.7 Million to Fund Operations Through up to Four Potential Clinical Proof-of-Concept Data Sets CARLSBAD, Calif., May 07, 2025 (GLOBE NEWSWIRE) -- Design Therapeutics, Inc. (Nasdaq: DSGN), a clinical-stage biotechnology company developing treatments for serious degenerative genetic diseases, today announced progress across its portfolio of GeneTAC® candidates and reported financial results for the first quarter 2025.
globenewswire.com
a month ago
Phase 2 biomarker trial in FECD patients anticipated to begin in the second half of 2025 Phase 2 biomarker trial in FECD patients anticipated to begin in the second half of 2025
globenewswire.com
a month ago
CARLSBAD, Calif., April 21, 2025 (GLOBE NEWSWIRE) -- Design Therapeutics, Inc. (Nasdaq: DSGN), a clinical-stage biotechnology company developing treatments for serious degenerative genetic diseases, today announced that it will present an update on the progress of its DT-168 program for Fuchs endothelial corneal dystrophy (FECD) at Eyecelerator @ Park City 2025 on Friday, May 2, 2025, at 1:30 p.m. MT in Park City, UT. The presentation will include safety findings from the Phase 1 single- and multiple-ascending dose trial of DT-168 in healthy adult volunteers and plans for Phase 2 clinical development in FECD patients.
globenewswire.com
a month ago
CARLSBAD, Calif., April 17, 2025 (GLOBE NEWSWIRE) -- Design Therapeutics, Inc. (Nasdaq: DSGN), a clinical-stage biotechnology company developing treatments for serious degenerative genetic diseases, today announced the appointment of Chris M.
zacks.com
3 months ago
Design Therapeutics (DSGN) might move higher on growing optimism about its earnings prospects, which is reflected by its upgrade to a Zacks Rank #2 (Buy).
globenewswire.com
3 months ago
Initiated Phase 1 Single Ascending Dose Trial of DT-216P2 in Healthy Volunteers; Friedreich Ataxia (FA) Patient Dosing to Begin in mid-2025
globenewswire.com
3 months ago
CARLSBAD, Calif., March 03, 2025 (GLOBE NEWSWIRE) -- Design Therapeutics, Inc. (Nasdaq: DSGN), a clinical-stage biotechnology company developing treatments for serious degenerative genetic diseases, today announced that management will participate in a fireside chat during Leerink's Global Healthcare Conference on Monday, March 10, 2025, at 1:40 p.m. ET in Miami.
globenewswire.com
7 months ago
CARLSBAD, Calif., Nov. 13, 2024 (GLOBE NEWSWIRE) -- Design Therapeutics, Inc. (Nasdaq: DSGN), a clinical-stage biotechnology company developing treatments for serious degenerative genetic diseases, today announced that management will participate in the following upcoming investor conferences:
See all news
